Evidence map›Paper›PMID 33070770›Full record

Trial reportCurrent clinical pharmacology2020

Prenatal Administration of Betamethasone and Neonatal Respiratory Distress Syndrome in Multifetal Pregnancies: A Randomized Controlled Trial.

Fatemeh Abbasalizadeh, Khadijeh Pouya, Raana Zakeri, Rana Asgari-Arbat, Shamsi Abbasalizadeh, Neda Parnianfard

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Current clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Fatemeh AbbasalizadehDepartment of Obstetrics and Gynecology, School of Medicine, Women's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Khadijeh PouyaDepartment of Obstetrics and Gynecology, Ankara University School of Medicine, Ankara, Turkey.
Raana ZakeriDepartment of Health Services Management, School of Management and Medical Informatics, Iranian International Safe Community Support Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Rana Asgari-ArbatDepartment of Obstetrics and Gynecology, School of Medicine, Women's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Shamsi AbbasalizadehDepartment of Obstetrics and Gynecology, School of Medicine, Women's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Neda ParnianfardResearch Center for Evidence-Based Medicine, Drug Applied Research Center, Health Management and Safety Promotion Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Tabriz University of Medical Sciences · IRAnkara University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeonatal Respiratory Distress Syndrome (NRDS) is one of the most frequent causes of neonatal mortality especially in premature infants. Although it has been well established that maternal antenatal corticosteroid therapy has a positive effect on NRDS reduction, yet the effectiveness of this treatment in multifetal pregnancies is dubious.

objectiveWe aimed to investigate the effect of betamethasone therapy on the incidence of NRDS in multifetal pregnancies through a randomized controlled trial.

methods140 women with a multifetal pregnancy at less than 28 weeks' gestational age were randomly allocated into intervention and control groups. Women at the intervention group received intramuscularly betamethasone (12 mg/kg/BW twice). Neonatal outcomes were evaluated between two groups of intervention and control, and two subgroups of preterm and term births. This study is registered with the Iranian Clinical Trials Registry, number IRCT20180227038879N1.

resultsThe incidence of NRDS was significantly lower in infants of betamethasone group than the ones in the control group (4.9% vs 18.1%, P=0.034) while it did not show a significant reduction in preterm infants compared to mature ones. Also, the intervention group presented a significant lower neonatal ventilation than the control group (47.2% vs 63.2%, P=0.041). Other neonatal outcomes, including age at birth, birth weight, Apgar score, NICU admission, and the number of mortalities were not significantly different between study groups.

conclusionBetamethasone therapy during 28-32 weeks of gestation in multifetal pregnancies was associated with better neonatal outcomes through significant reductions in NRDS incidence and requiring ventilator treatment. However, betamethasone administration did not reduce the chance of NRDS in premature infants.

Indexed as

Prenatal CareAdultBetamethasoneFemaleGestational AgeGlucocorticoidsHumansInfant, NewbornInfant, PrematureInjections, IntramuscularIntensive Care Units, NeonatalIranMalePatient AdmissionPregnancyPregnancy, MultipleBetamethasoneGlucocorticoidsantenatal corticosteroidbetamethasoneclinical trialgestationmultifetal pregnanciesNeonatal respiratory distress syndrome

Identifiers

PMID33070770
PMCPMC7579252
OpenAlexW2979707583

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.